FIRST AMENDMENT AND LIMITED WAIVER TO CREDIT AND GUARANTY AGREEMENTCredit and Guaranty Agreement • August 5th, 2021 • Athenex, Inc. • Pharmaceutical preparations • New York
THIS FIRST AMENDMENT AND LIMITED WAIVER TO CREDIT AND GUARANTY AGREEMENT (this “Amendment”), dated as of June 3, 2021 (the “Amendment Effective Date”), is made by and among ATHENEX, INC., a Delaware corporation (the “Borrower”), the Lenders party hereto and OAKTREE FUND ADMINISTRATION, LLC, as administrative agent for the Lenders (in such capacity, the “Administrative Agent”).
AMENDED AND RESTATED EXCLUSIVE LICENSE AND OPTION AGREEMENT BY AND BETWEEN BAYLOR COLLEGE OF MEDICINE ANDExclusive License and Option Agreement • August 5th, 2021 • Athenex, Inc. • Pharmaceutical preparations • New York
This Amended and Restated Exclusive License and Option Agreement (the “Restated Agreement”), effective as of February 28, 2020 (the “Restatement Effective Date”), is by and between Baylor College of Medicine (“Baylor”), a Texas nonprofit corporation having its principal place of business at One Baylor Plaza, Houston, Texas 77030, and Kuur Therapeutics Limited (formerly known as Cell Medica, Ltd.) (Reg. No. 05620555), a private limited company organized under the laws of England and Wales and having a principal place of business at 1 Canal Side Studios, 8-14 St Pancras Way, London, NW1 0QG, United Kingdom (“Cell Medica” or “Kuur”). As of the Restatement Effective Date, this Restated Agreement amends and restates the License and Option Agreement dated April 29, 2016, as amended by that certain First Amendment dated May 26, 2017, that certain Second Amendment dated December 5, 2017, that certain Third Amendment dated May 17, 2018, that certain Fourth Amendment dated December 19, 2018, and
AMENDED AND RESTATED CO-DEVELOPMENT AGREEMENT BY AND BETWEEN BAYLOR COLLEGE OF MEDICINE AND KUUR THERAPEUTICS LIMITED (f/k/a CELL MEDICA, LTD.) Original Effective Date: APRIL 29, 2016 Restatement Effective Date: FEBRUARY 28, 2020Co-Development Agreement • August 5th, 2021 • Athenex, Inc. • Pharmaceutical preparations • New York
This Amended and Restated Co-Development Agreement (the “Restated Agreement”), effective as of February 28, 2020 (the “Restatement Effective Date”), is by and between (i) Baylor College of Medicine (“Baylor”), a Texas nonprofit corporation having its principal place of business at One Baylor Plaza, Cullen Building, Suite 106A, Houston, Texas 77030, and (ii) Kuur Therapeutics Limited (formerly known as Cell Medica, Ltd.) (Reg. No. 05620555), a private limited company organized under the laws of England and Wales and having a principal place of business at 1 Canal Side Studios, 8-14 St Pancras Way, London, NW1 0QG, United Kingdom (“Cell Medica” or “Kuur”). As of the Restatement Effective Date, this Restated Agreement amends and restates the Co-Development Baylor Agreement enter into by Baylor and Cell Medica dated April 29, 2016, as such agreement has been amended by that certain First Amendment dated July 12, 2017 and that certain Second Amendment dated February 28, 2019 (collectively,
